A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC)
NCT ID: NCT00002170
Last Updated: 2005-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nelfinavir mesylate
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HIV infection
* New diagnosis of MAC bacteremia and \< 7 days of therapy.
Prior Medication:
Allowed:
Patients no more than 7 days of therapy for MAC disease.
Exclusion Criteria
Excluded:
Prior therapy (or less than 2 weeks) with protease inhibitors other than saquinavir.
13 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Agouron Pharmaceuticals
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Univ of California / San Diego Treatment Ctr
San Diego, California, United States
Harbor UCLA Med Ctr
Torrance, California, United States
Rush Presbyterian - Saint Luke's Med Ctr
Chicago, Illinois, United States
Boston VA Med Ctr / 151
Boston, Massachusetts, United States
Baylor Univ
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Study 518
Identifier Type: -
Identifier Source: secondary_id
AG1343-518
Identifier Type: -
Identifier Source: secondary_id
259C
Identifier Type: -
Identifier Source: org_study_id